



Article

Glutathione–Allylsulfur Conjugates as Mesenchymal Stem Cells Stimulating Agents for Potential Applications in Tissue Repair

Emilia Di Giovanni ¹, Silvia Buonvino ¹, Ivano Amelio ² and Sonia Melino ^{1,3,*}

¹ Department of Chemical Science and Technologies, University of Rome Tor Vergata, via della Ricerca Scientifica 1, 00133 Rome, Italy; emilia.digiovanni8@gmail.com (E.D.G.); s.buonvino@alice.it (S.B.)

² MRC Toxicology Unit, University of Cambridge, Cambridge CB2 1QP, UK; ia348@mrc-tox.cam.ac.uk

³ CIMER Center for Regenerative Medicine, University of Rome Tor Vergata, via Montpellier 1, 00166 Rome, Italy

* Correspondence: melinos@uniroma2.it; Tel.: +39-06-72594410; Fax: +39-06-72594328

Received: 4 January 2020; Accepted: 25 February 2020; Published: 28 February 2020



Abstract: The endogenous *gasotransmitter* H₂S plays an important role in the central nervous, respiratory and cardiovascular systems. Accordingly, slow-releasing H₂S donors are powerful tools for basic studies and innovative pharmaco-therapeutic agents for cardiovascular and neurodegenerative diseases. Nonetheless, the effects of H₂S-releasing agents on the growth of stem cells have not been fully investigated. H₂S preconditioning can enhance mesenchymal stem cell survival after post-ischaemic myocardial implantation; therefore, stem cell therapy combined with H₂S may be relevant in cell-based therapy for regenerative medicine. Here, we studied the effects of slow-releasing H₂S agents on the cell growth and differentiation of cardiac Lin[−] Sca1⁺ human mesenchymal stem cells (cMSC) and on normal human dermal fibroblasts (NHDF). In particular, we investigated the effects of water-soluble GSH–garlic conjugates (GSGa) on cMSC compared to other H₂S-releasing agents, such as Na₂S and GYY4137. GSGa treatment of cMSC and NHDF increased their cell proliferation and migration in a concentration dependent manner with respect to the control. GSGa treatment promoted an upregulation of the expression of proteins involved in oxidative stress protection, cell–cell adhesion and commitment to differentiation. These results highlight the effects of H₂S-natural donors as biochemical factors that promote MSC homing, increasing their safety profile and efficacy after transplantation, and the value of these donors in developing functional 3D-stem cell delivery systems for cardiac muscle tissue repair and regeneration.

Keywords: hydrogen sulfide; garlic; regenerative medicine; oxidative stress; MSCs; organosulfur compounds; cell migration; cell differentiation

1. Introduction

The *gasotransmitter* H₂S is a physiological signalling molecule in mammalian cells that stimulates important molecular pathways [1–3]. Endogenous H₂S is produced in tissues from L-cysteine by the activity of cystathionine γ -lyase (CSE), cystathionine β -synthase (CBS), thiosulfate:cyanide sulphurtransferase (TST, EC. 2.8.1.1; rhodanese) and 3-mercapto-pyruvate sulfurtransferase (3-MST) [4–6]. In the last decade slow H₂S-releasing donors have been suggested as exogenous sources for therapeutic applications in cardiovascular [7–9], neurodegenerative [1,4,10] and gastrointestinal diseases [11,12]. One of most relevant problems in the H₂S-based therapy is the identification of an appropriate posology and an accurate administration protocol of H₂S donors, in order to avoid the high risk of overdosing. Therefore, slow H₂S releasing agents, such as garlic derivatives, seem to exhibit the pharmacological features needed to generate H₂S with a controlled rate and represent an interesting natural alternative

for therapeutic applications. Organo-sulfur compounds (OSCs) derived from the garlic compound alliin, such as S-allylcysteine (SAC) diallyldisulfide (DADS) and diallyltrisulfide (DATS), have been recognized to have potential pharmacological properties, related to the H₂S signaling pathway [13,14]. In particular, the allylsulfides DADS and DATS, which are the major components of oil-soluble garlic extract, are H₂S slow-releasing donors. Their intracellular H₂S-release mechanism requires the cooperation of reduced GSH, as elucidated by Kraus et al. [13]. In regards to the α carbon of a diallyl polysulphide, GSH acts as a nucleophilic substituent and the nucleophilic substitution leads to S-allyl glutathione and allyl perthiol [13]. By thiol/disulphide exchange with GSH, allyl perthiol can be transformed either into allyl glutathione disulphide (GSSH) and H₂S, or into H₂S₂ and S-allyl glutathione through a nucleophilic substitution by GSH at the α -carbon. Finally, H₂S₂ can interact with GSH, resulting in GSSH and H₂S. Therefore, polysulfides have recently been considered potential physiological mediators that are able to activate membrane channels, enzymes, and transcription factors by sulfhydration mechanism. The cytotoxicity of OSCs and H₂S-donors in general likely depends on their concentration per cell and on their metabolic rate in the cells, which in turn depends on the cell type. The exogenous H₂S can have pro- [15–18] or anti-apoptotic effects [19–22], depending on the individual cell phenotype and on the experimental settings used, such as the concentration of H₂S. Previous studies suggest that garlic-derived OSCs selectively induce programmed cell death in neoplastic cells but not in their physiological counterparts or adult stem cells [23–30]. H₂S is able, in fact, to improve cell survival in a cell-specific manner by activation of molecular signalling [31]. H₂S represses programmed cell death and inflammation by downregulation of inflammatory cytokines, such as, for example, TNF- α , IL-1b, NF-kB, IL-8 and IL-6 [32–35]; furthermore, it regulates blood pressure-lowering, and exerts anti-nociceptive and cardioprotective effects due to the activation of cardiac extracellular signal-dependent-kinases, such as Akt pathways and K_{ATP} channels [36,37].

To assess the effects of H₂S-donors with antitumor properties on adult stem cells, in this study, water-soluble glutathione-garlic extract (GSGa) was produced using the protocol previously described [16,38], and it was used for treatment of human adult stem cells. GSGa is a particular extract rich in glutathione-conjugates with pro-apoptotic properties on cancer cell lines and the ability to promote their G2/M phase cell cycle arrest [16]. The data herein presented demonstrate that, in contrast with the effects on tumor cells, GSGa treatment of cardiac Lin⁻ Sca-1⁺ human mesenchymal stem cells (hereinafter, cMSC) improves their viability, proliferation and migration rate, without affecting their plasticity. The effects of the treatment on cMSC were also compared with other H₂S-donors, such as Na₂S and GYY4137. Our previous studies performed on other H₂S releasing systems (nanoemulsions, hydrogels and nanofibers) showed that the H₂S release improves the proliferation of cMSC, as well as of normal human dermal fibroblasts (NHDF), and increases the expression of proteins related to cell–cell interaction, such as connexin 43, and cell survival under oxidative stress [38–40]. H₂S-donors, in fact, display relevant antioxidant properties; they can either act as reducing agents/scavengers by directly reacting with ROS species or rescue the cells from oxidative stress by promoting glutathione production, which is the most abundant and potent intracellular antioxidant species [41]. Exogenous H₂S can protect primary rat cortical neurons from oxidative stress, so it can be a powerful neuroprotective agent due to its cytoprotective, anti-inflammatory, antioxidant and anti-apoptotic properties [41–44]. Furthermore, recent studies demonstrate that H₂S preconditioning protects bone marrow-derived mesenchymal stem cells (BMSCs) from hypoxia, and biologically-active factors released by conditioned-H₂S BMSCs provide protection of neurons exposed to ischaemic conditions [45]. On these bases, we investigated the antioxidant properties of GSGa, demonstrating its ability to inhibit cell death induced by ROS damage or CoCl₂ in cMSC and normal human dermal fibroblasts (NHDF). These properties were related to an upregulation of antiapoptotic and antioxidant proteins, such as Bcl2, NAD(P)H quinone oxidoreductase 1 (NQO1) and thioredoxin (Trx). Furthermore, a prolonged treatment of cMSC with GSGa allowed us to obtain a selected cMSC line, named GcMSC, which showed an increased proliferation and migration rate as well as resistance to oxidative stress, while preserving the stem cell

multi-potency. Therefore, these results suggest a potential use of prolonged treatment with H₂S-donors for the optimization of adult stem cells for tissue engineering and repair.

2. Results

2.1. H₂S-Donors Promote Proliferation and Migration of cMSC

The effects of H₂S on stem cells have not been fully investigated. To further study the effect of H₂S donors on human adult stem cells, Na₂S, GYY4137 and water-soluble garlic extracts (GSGa) were used for the treatment of cMSC. In Figure 1, the effects of H₂S releasing agents on the cell proliferation of cMSC are shown. Cell viability was analyzed after three days of treatments with different H₂S-donors and, in general, an increase of cMSC proliferation in a concentration-dependent manner was observed with respect to the control, especially after treatment with GYY4137 and GSGa (Figure 1b,c). Notably, Na₂S treatment induced a decrease in proliferation at 25 and 50 μM concentrations, probably due to a direct cytotoxic effect for the high concentrations of H₂S. By contrast, at higher H₂S concentrations, 100 and 200 μM, an increase in cell proliferation was observed after 3 days of growth (Figure 1a).




Figure 1. Effects of H₂S slow-releasing agents on cell proliferation and migration of cMSC. Cell proliferation of cMSC (5×10^3 cells/cm²) after 3 days of treatment at different concentrations of (a) Na₂S (25, 50, 100 and 200 μM) and (b) GYY4137 (25, 50, 100 and 200 μM); (c) cell proliferation of cMSC treated for 3 days with 5 and 10 μL of Ga (141 mg/mL d.w) and 5, 10 and 20 μL of GSGa (136 mg/mL d.w). (d) Bright field micrographs of cMSC cultured for 3 days in the presence and in the absence of 136 μg/mL of GSGa. (e) Scratch wound healing assay on cMSC cultured in the absence (cMSC) or in the presence of 680 μg/mL of GSGa (+GSGa). Micrographs in the upper and lower panels were taken immediately after the scratching (0 h) and after 48 h (48 h) respectively; cells shown in the lower panels were stained with crystal violet dye. Quantification of wound closure was calculated by three independent experiments. Error bar indicates S.D.; $n = 3$ or 5. Statistical significance is shown as * p value ≤ 0.05 , ** p value ≤ 0.01 , *** p value ≤ 0.005 .

Both GYY4237 and GSGa induced an increase in the cell proliferation in a concentration dependent manner. After three days of treatment with 680 μg/mL of GSGa, a statistically significant increase of up to $170.3 \pm 41.99\%$ of cell proliferation with respect to the control was observed (Figure 1c). By contrast, the treatments with both water-soluble garlic extracts obtained without reaction with GSH (Ga) and GSH, at similar concentrations used for the GSGa treatment, did not induce an increase in cell viability, demonstrating that the relevant role on the induction of the stem cell proliferation by GSGa treatment is due to the presence of glutathionyl-conjugates. A cell proliferation increase due to the

GSGa treatment was also confirmed by microscopy analysis, as shown by micrographs of the cells after three days culture in the presence or in the absence of 136 $\mu\text{g}/\text{mL}$ of GSGa (Figure 1d). The proliferation and migration were also assessed by scratch test (Figure 1e); the cell cultures after 48 h in the presence of GSGa showed a closer scratch than in the absence, probably due to concomitant increase in both cell migration and proliferation.

2.2. Antioxidant Properties of GSGa and Increase in cMSC Survival under a Chemical Hypoxia-Mimicking Agent

The antioxidant properties of the GSGa was tested using a pDNA damage assay based on assessing the cleavage effect of oxidant species such as H_2O_2 or Cu^{2+} and Co^{2+} ions in the presence of ascorbic acid (Figure 2a,b). The presence of GSGa at 10.8 $\mu\text{g}/\mu\text{L}$ inhibited the pDNA cleavage obtained in both cases: after incubation with 100 μM of H_2O_2 and after incubation with 100 μM of Cu^{2+} and 10 mM ascorbic acid. The pDNA cleavage was also reduced in the presence of 100 μM of CoCl_2 and 10 mM ascorbic acid by addition of GSGa, as shown by the presence of the supercoiled form of the pDNA and the reduced presence of a cleaved form after treatment with CoCl_2 (Figure 2b). The effects of CoCl_2 on the cMSC viability were also studied in the presence and in the absence (see also Figure S2 in Supplementary Materials) of 680 $\mu\text{g}/\text{mL}$ of GSGa in the cell culture medium (Figure 2c), showing a protective anti-hypoxic effect of the GSGa, in turn resulting in an increase of 15% in cell survival in the presence of 0.25 mM of CoCl_2 . An increase in the expression of HIF-1 α was observed under CoCl_2 treatment in the presence of GSGa (Figure 2d).




Figure 2. Antioxidant properties of GSGa. (a) Inhibition of pDNA cleavage by GSGa; 0.5 μg of pDNA after addition of H_2O_2 (100 μM) or CuCl_2 (100 μM) and ascorbic acid (10 mM) in 20 mM Tris HCl, pH 7.4, buffer after 0 (lane 1) or 15 min (lane 2) of incubation at 37 $^\circ\text{C}$ in the absence (lane 3, 4, 7 and 8) or in the presence (lane 5, 6, 9 and 10) of 10.8 $\mu\text{g}/\mu\text{L}$ of GSGa. (b) 0.5 μg of pDNA after addition of CoCl_2 (100 μM) and ascorbic acid (10 mM) in 20 mM Tris HCl, pH 7.4, buffer after 0 (lane 1) and 15' (lane 2) incubation at 37 $^\circ\text{C}$ in the absence (lane 3 and 4) or in the presence (lane 5 and 6) of 10.8 $\mu\text{g}/\mu\text{L}$ of GSGa. Note: (∞), (o), (-) and (c) are respectively the supercoiled, circular, linear and cleaved pDNA forms. (c) Cell viability of cMSC (by MTT assay) after 40 h of treatment with 0, 0.25 and 0.5 mM of CoCl_2 in the presence (+GSGa) or in the absence (cMSC) of 680 $\mu\text{g}/\text{mL}$ of GSGa. The integral images of the gels are reported in the Supplementary Materials (Figure S3). (d) western blot and densitometric analysis of HIF-1 α expression in cMSC after exposure to CoCl_2 in the presence or in the absence of GSGa in the culture medium. Error bar indicates S.D. Blots are a representative experiment of three independent experiments. ** p value < 0.01 (one-way ANOVA test).

Therefore, the cytoprotective effect of GSGa against CoCl_2 could promote the expression of hypoxia-responsive element (HRE)-controlled genes by reduction of HIF-1 α subunit degradation.

2.3. GSGa Improves Cell Survival under Oxidative Stress

H_2S is a physiological mediator that limits inflammation and free radical damage [46] and is able to upregulate ARE-gene transcription [47]. In Figure 3, the protective effects of the pretreatment with GSGa from the oxidative damage induced by H_2O_2 on NHDF and cMSC cultures are shown. Figure 3a shows the micrographs of NHDF after 12 h of H_2O_2 exposure and pretreating with GSGa. After three days of growth in the presence (GSGa) or in the absence (NHDF) of 680 $\mu\text{g}/\text{mL}$ of GSGa, the cells were re-seeded, and after adhesion (6 h from seeding), H_2O_2 was added to the cell culture medium at a final concentration of 100 μM . Pretreatment with GSGa induced major resistance to the oxidative stress due to presence of H_2O_2 , as was observable by the presence of a larger number of the cells in the well (Figure 3a,b).




Figure 3. Antioxidant effect of GSGa on cells. (a) Micrographs of NHDF after 0 and 12 h of treatment with H_2O_2 (100 μM), with (+GSGa) or without (NHDF) the addition of 680 $\mu\text{g}/\text{mL}$ GSGa (see also Figure S5); (b) micrographs of cMSC (CTRL) after 24 h of treatment with H_2O_2 (100 μM), with or without the addition of 680 $\mu\text{g}/\text{mL}$ of GSGa. Cells were dyed with crystal violet; (c) Cell viability of cMSCs after 24 h of growth in the presence of H_2O_2 (100 μM) (cMSC) (as control) and in the presence of 680 $\mu\text{g}/\text{mL}$ of GSGa (+GSGa) or Na_2S (95 μM) or GSH (100 mM); (d) FACS cell cycle analysis of cMSC cultured for 24 h in the presence of H_2O_2 (100 μM) and with addition of either GYY4137 (80 mM) or GSGa (680 $\mu\text{g}/\text{mL}$). Error bar indicates S.D. Experiments were performed in three or five biological replicas. **** p valule ≤ 0.0001 (one-way ANOVA).

Moreover, the presence of GSGa in the medium significantly prevented H_2O_2 -induced cell death of cMSC (Figure 3b). To determine whether GSGa treatment of cMSC could protect from oxidative damage, cMSC were treated with 100 μM H_2O_2 for 24 h either in the presence or in the absence of 680 $\mu\text{g}/\text{mL}$ of GSGa (Figure 3c). An increase of 36.7% cell survival in the presence of GSGa with respect to its absence was observed. Furthermore, the effect due to the presence of GSH and Na_2S in the medium was also analyzed, resulting in cell viability of 89.7%, compared to 44.4% cell viability without H_2O_2 . The FACS cell cycle profiles after treatment confirmed the increased percentage of cMSC in the subG_1 -phase after treatment with H_2O_2 , which was not observable in the presence of GSGa, confirming

the antioxidant properties of the glutathione-conjugate extract. Moreover, in the presence of a known H₂S-donor, such as GYY4137, the same decrease in the *subG*₁-phase was not detected (Figure 3d).

2.4. GSGa Increases the Expression of Pro-Cell Survival and Differentiation-Associated Markers

The molecular mechanisms underlying GSGa's cytoprotective effect on both NHDF and cMSC were investigated using western blot analysis of the cellular extract after 3 days of treatment with GSGa (680 µg/mL). The expression of the proteins involved in the cellular redox system, such as thioredoxin 1 (Trx1) and NQO1, and the anti-apoptotic protein Bcl2, were substantially increased after treatment with GSGa (Figure 4a,b). In particular, Bcl2 was increased up to 10 times compared to control non-treated cMSC (Figure 4a).




Figure 4. Effects of the GSGa on the protein expression. (a) Representative western blot analysis of the expression of p-ERK1/2, Bcl2, Trx1 and GAPDH in cMSC cultured for 3 days in the presence (+GSGa) or in the absence (cMSC) of 680 µg/mL of GSGa; (b) Representative western blot analysis of the expression of NQO1, GAPDH in both cMSCs and NHDFs cultured for 3 days in the presence (+GSGa) or in the absence (MSC or NHDF) of 680 µg/mL of GSGa, The integral figure of the NHDFs blot and the original western blot of MSC for NQO1 expression are shown in the Supplementary Materials (Figures S9 and S10); (c) Representative western blot analysis of the expression of p(Ser 473)Akt in cMSC after 3 days of treatment with (+GSGa) or without (cMSC) GSGa, GAPDH expression was used as normalization control. Error bar indicates s.e.m or S.D. Experiments were performed in three or five biological replicas (one-tailed Student's t-test).

Furthermore, to determine the potential pathways involved in the GSGa-mediated pro-cell survival effect, the activation of extracellular signal-regulated kinases ERK1/2 and Akt, also known as protein kinase B, was observed in cMSC after GSGa treatment (Figure 4a,c). An increased activation of ERK1/2 (p-ERK1/2) was observed in treated cMSC compared to control (Figure 4a), therefore ERK1/2 could be responsible for the pro-survival and anti-apoptotic effect of GSGa. After three days of cell culture in the presence of 680 µg/mL of GSGa (Figure 4c), the intracellular level of p(Ser 473)-Akt in cMSC was increased.

The expression of proteins involved in the commitment of the cardiac muscle phenotype differentiation was also assessed by fluorescence microscopy and western blot analysis. Figure 5a,b

show the fluorescence micrographs of cMSC after 3 days of growth in the presence and in the absence of 680 $\mu\text{g}/\text{mL}$ of GSGa. An increased expression of the proteins α -smooth muscle actin (α -SMA) and connexin 43 (Cx43) were observed in the cMSCs cultured in the presence of GSGa and the increased expression was maintained over time after 6 or 7 days of treatment (Figure S7 in Supplementary Materials). As shown in Figure 5c, treatment of cMSC with 680 $\mu\text{g}/\text{mL}$ of GSGa led to a significant increase of the expression of α -SMA and Cx43 proteins.




Figure 5. GSGa increases the expression of cardiac phenotype markers. Fluorescent micrographs of 5×10^3 cells/ cm^2 of cMSC cultured for 3 days in the presence (GSGa) and in the absence of 680 $\mu\text{g}/\text{mL}$ of GSGa, (a) α -SMA expression is shown in red and (b) Cx43 is stained in green; (c) western blotting and densitometric analysis of the protein expression in cMSC after 3 days of treatment with 680 $\mu\text{g}/\text{mL}$ of GSGa. The expression of the proliferation marker and the proteins Cx43 and α -SMA was significantly upregulated after treatment compared to the control. Images are representative of five independent experiments. Error bar indicates S.D. Experiments were performed as three biological replicas. * p value ≤ 0.05 (one-tailed Student's t -test).

2.5. Prolonged Treatment with GSGa Stimulates Cell Proliferation, Resistance to Oxidative Stress and Migration of cMSC

Thanks to the cytoprotective properties of H_2S -donors, the preconditioning of stem cells before their transplantation has recently gained attention. On this basis, we performed a prolonged pretreatment of the cells using a low concentration of GSGa with the aim to select cMSC with more resistant features to the oxidative stress compared to non-treated cells. In detail, cMSC were cultured for one month in the presence of 140 $\mu\text{g}/\text{mL}$ of GSGa and the selected line was named GcMSC. The resistance to oxidative stress was tested by exposure of cMSC and GcMSC to 100 μM H_2O_2 for 24 h. Figure 6a shows the representative optical micrographs of the cells after H_2O_2 treatment, where it is evident that the GcMSCs had higher cell density and improved morphology compared to cMSC after treatment.




Figure 6. Prolonged GSGa treatment for selection of oxidation-resistant cMSC line. (a) Micrographs of cMSC and GcMSC seeded at 1×10^4 cells/cm² of density, after 24 h from seeding in the presence or absence of H₂O₂ (100 μM). Scale bars are 100 μm. Cells were stained using crystal violet. (b) Cell viability of control (cMSC), GcMSC (GcMSC) and of GcMSC in the presence also of 680 μg/mL of GSGa (GcMSC+GSGa) after 24 h of treatment with H₂O₂ (100 μM). The data were obtained by five independent experiments and analyzed using ANOVA one-way test. (c) Optical micrographs of cMSC and GcMSC (1×10^4 cells/cm² of density) at 0 or 12 h of treatment with H₂O₂ (100 μM). Scale bars are 100 and 50 μm; (d) FACS profiles (on the top) and histograms of the cell cycle distribution (on the bottom) of cMSC (as control) and GcMSC cultured for 12 h in the presence or in the absence of H₂O₂ (100 μM). (e) Representative western blot analysis of the expression of Bcl2, Trx1 in cMSC and GcMSC. The original figure is shown in the Supplementary Materials Figure S9. Experiments were performed as three biological replicas. Error bar indicates S.D. ** p value ≤ 0.01 ; **** p value ≤ 0.0001 (one-way ANOVA).

This result was also confirmed by a WST-1 viability assay (Figure 6b). GcMSC showed a survival of up to $15 \pm 5.3\%$ higher than the cMSC used as control. Notably, further addition of GSGa to the medium of the GcMSC culture, led to a survival of $42.5 \pm 5.7\%$. This last value was higher than that obtained with only the addition of GSGa ($36.7\% \pm 7.67$, Figure 3c) without preconditioning.

GcMSC were more resistant than cMSC to the oxidative damage by the cellular density after 12 h of treatment with H₂O₂ (Figure 6d). This finding was also confirmed by the cell cycle analysis, which showed that the percentage of the GcMSC population in the *subG*₁-phase was half that of cMSC. This increased resistance to the oxidative stress was also in agreement with higher levels of expression of proteins associated with pro-survival Bcl2 and Trx1 in GcMSC compared to those in cMSC (Figure 6e and Figure S6b in Supplementary Materials). The cell migration ability was also tested using both the percentage of scratch wound closure after 48 h, shown in Figure 7a, and the trans-well migration through the membrane after 6 h. In both cases, the GcMSC migration was significantly higher than that of cMSC.




Figure 7. Prolonged GSGa treatment improves cMSC migration. (a) Scratch wound healing assay of GcMSC and cMSC; micrographs in the upper and lower panels were taken immediately after the scratching (0 h) and after 48 h of growth respectively. The quantification of the wounded area invaded was calculated by two independent experiments. (b) Micrographs of a 6 h trans-well migration assay of GcMSC and control cMSC. Cells were stained with crystal violet dye. Scale bars are 200 μm in panel A, and 50 μm (upper) and 30 μm (lower) in panel B, respectively. * p value ≤ 0.05 (one-tailed Student's t-test). Error bar indicates s.e.m.

2.6. Prolonged Treatment with GSGa Does Not Affect the Mesenchymal Stem Cell Plasticity

To assess the multipotency of the GcMSC, they were subjected to different differentiation protocols. As shown in Figure 8, GcMSC were able to differentiate into different cell types: osteoblasts, adipocytes, chondrocytes and cardiocytes. In particular, the cardiogenic differentiation was assessed by the expression of human troponin T2 (TNNT2). The microscopic analyses of the cells did not show any relevant differences between the cell plasticity of GcMSC and cMSC.




Figure 8. Multipotency of cMSC and GcMSCs. Chondrogenic, adipogenic and osteogenic differentiation of cMSC and GcMSC (cMSC pretreated with 136 $\mu\text{g/mL}$ of GSGa for one month). The cells were stained using Alizarin red S, AdipoRed and Alcian blue dyes for osteogenic, adipogenic and chondrogenic differentiation, respectively. For cardiogenic differentiation, cells were stained using an anti-TNNT2 and an Alexa Fluor[®] 488 donkey anti-mouse secondary antibody. Scale bars are 5, 10, 50 μm as indicated. Experiments were performed as three biological replicas.

2.7. GSGa Treatment of cMSCs Modulates the Expression of Genes Related to the Cardiovascular Disease and Detoxification Enzymes

To determine the signaling pathways modulated by the treatment with GSGa, the global transcriptional profile (50,599 genes) of cMSCs was analyzed by gene microarray analysis. In total, 388 and 165 genes showed modulated expression in the cMSCs treated for 3 days with GSGa and in the GcMSCs, respectively, compared with the control. In detail, 266 genes were downregulated and 122 were upregulated after GSGa treatment with respect to the control, while 77 genes were upregulated and 88 downregulated in GcMSC with respect to cMSC. Figure 9a shows the respective heat-maps. Volcano plots from microarray analysis are shown in Figure S8 (in Supplementary Materials). Venn diagram (see Figure 9b) of cMSC vs. GSGa and cMSC vs. GcMSC shows that 36 genes were regulated in both acute and prolonged preconditioning. Interestingly, the transcription of genes involved in the metabolism of xenobiotics and the MAPK signaling pathway, such as cytochrome P450 and myocyte enhancer factor 2C (MEF2C), was changed, after both the preconditioning treatments (see Table S1 in Supplementary Materials). However, these results must be confirmed by protein expression analysis.




Figure 9. Transcriptional profiling of cMSC following GSGa treatment. (a) Heat-maps show significantly upregulated and downregulated genes in cMSC following prolonged (GcMSC/cMSC) or 3-day (GSGa/cMSC) GSGa treatment and those in GSGa with respect to GcMSCs (GcMSC/GSGa). Heat-maps were generated by hierarchical clustering of genes accordingly to the fold change. Cut-off p value ≤ 0.05 ; Cut off fold change 1.5. (b) Venn diagram depicts overlap of differentially regulated genes after 3 days (GSGa) and 30 days (GcMSC) of treatment. The diagram has been generated by using InteractiVenn webtool (<http://www.interactivenn.net>) inputting the probe name lists from the gene array data. (c) Selection of significantly upregulated genes following GSGa treatment whose function was associated with cardiovascular diseases. (d) Histograms show gene expression variation (upregulation: up; downregulation: down) after GSGa treatment (GSGa) of genes associated with the diseases indicated in the legend.

Among the proteins upregulated after treatment, four proteins were found to be either downregulated or not expressed at all in certain cardiovascular diseases. In particular, the protein tyrosine-protein kinase receptor (TYRO3) was found to be upregulated in treated cMSC, while its expression is reported to be downregulated in atherosclerotic carotid plaque [48]. Actinin alpha 2 (ACTN2) was also upregulated upon treatment with GSGa, while it has been reported to be downregulated in cardiomyopathy/dilated cardiomyopathy [49]. This protein is expressed in skeletal

and cardiac muscle tissue and it serves as a bridge for anchoring myofibrillar actin thin filaments and titin to Z-discs. Finally, two more proteins were found to be upregulated upon treatment: sarcoglycan delta (SGCD) and serum response factor binding protein 1 (SRFBP1), usually downregulated or mutated in hypertrophic and dilated cardiomyopathies and during heart failure, respectively [50,51].

The analysis, performed using DAVID 6.8 program (<https://david-d.ncicrf.gov/home.jsp>), of the functions of the genes both up and downregulated in cells after GSGa treatment with respect to the control showed that 52.5% of the genes whose expression was altered upon the treatment were linked to the cardiovascular system/cardiovascular diseases (approximately 24.3% were upregulated and the remaining 28.2% were downregulated), 33.4% of the altered genes were linked to neurodegenerative diseases (21.9% upregulated, 11.5% downregulated), and 18.6% were associated with diabetes (9.7% upregulated, 8.9% downregulated) (Figure 9c). The remaining 6.4% were associated with obesity and were all downregulated (Figure 9c).

3. Discussion

The water-soluble garlic extract, named GSGa, obtained by conjugation of garlic OSCs with glutathione was here investigated for its antioxidant properties and its ability to induce cell proliferation and migration in adult stem cells.

Recently, *in vivo* and *in vitro* studies have shown that NaHS is able to enhance the survival of bone marrow-derived mesenchymal stem cells (BMSC) upon hypoxia-ischaemic conditions [45]. Our results show an increase of the cMSC proliferation in a concentration-dependent manner with respect to the control after treatment with GYY4137 and GSGa. These data are in agreement with previous results demonstrating the ability of H₂S to promote neural stem cell proliferation and differentiation and to protect against hypoxia-induced decreases in hippocampal neurogenesis [52].

The cytotoxic effect observed at 50 μM of Na₂S could be compatible with a very fast H₂S-release, while at higher concentrations this initial cytotoxic effect was compensated by a positive effect on the cell growth of a slow H₂S release due to the protein S-sulfhydration. As already described, the cellular or tissue response may be influenced by the manner in which cells and tissues are exposed to H₂S [53]. Both Na₂S and NaHS instantaneously generate H₂S and are very short-lived compounds, indeed they are not ideal H₂S-donors for studying the physiology, whereas enzymatic or GSH-derived H₂S synthesis is considerably slower, over a much longer time [13,54–56]. The GSGa was also able to improve the stem cell migration as demonstrated by the scratch assays where the cell cultures after 48 h in the presence of GSGa showed a closer scratch than in the absence. This effect was probably due to concomitant increase in both cell migration and proliferation.

The antioxidant properties of the GSGa was also tested using a pDNA damage assay based on assessing the cleavage effect of oxidant species such as H₂O₂ or Cu²⁺ and Co²⁺ ions in the presence of ascorbic acid. The presence of GSGa inhibited the pDNA cleavage obtained in both H₂O₂, CuCl₂ and CoCl₂. GSGa showed a protective anti-hypoxic effect on the cMSC, leading to an increase of 15% in cell survival with increased expression of HIF-1α. The HIF-1α subunit of the heterodimeric transcription factor HIF is continuously synthesized, hydroxylated and degraded through the ubiquitin–proteasome system [57]. Under hypoxic or hypoxic-mimic conditions, such as after treatment with CoCl₂, a chemical hypoxia-mimicking agent, the prolyl-hydroxylase activity is inhibited and consequently HIF-1α is stabilized for translocation into the nucleus and dimerization with HIF-1β [58]. Active HIF-1 regulates the expression of genes involved in the anti-hypoxic/oxidant cellular response. Target genes of HIF-1 are involved in different biological pathways, such as energy metabolism, angiogenic signaling, growth, apoptosis, and cell migration [59]. The cytoprotective effect of GSGa against CoCl₂, similarly to other H₂S-donors [60], could reduce HIF-1α subunit degradation, promoting the expression of hypoxia-responsive element (HRE)-controlled genes.

During the last decade, it has been demonstrated that H₂S is a physiological mediator that limits inflammation and free radical damage [46] by reacting with multiple oxidant stressors including peroxynitrite [57], superoxide radical anion [61], and hydrogen peroxide [62]. Moreover, H₂S is

able to upregulate ARE-genes transcription [47] and also produce glutathione persulfide (GSSH) in mitochondria [63–65], a more efficient H_2O_2 -scavenging molecule than GSH. The pretreatment with GSGa of both NHDF and cMSC cultures led to an increase in cell survival from the oxidative damage induced by H_2O_2 .

The presence of GSGa led to an increased percentage of cells in the $S/M/G_2$ -phase, which could be related to both an increase of S -phase or a partial cell-cycle arrest in G_2 phase. This increased rate of MSCs in the $S/M/G_2$ -phase was not observed in the presence of GSGa, without the addition of H_2O_2 (see Figure S4 in Supplementary Materials). Therefore, the GSGa treatment could have both a direct protective effect against oxidative species, as demonstrated using the pDNA degradation assay, and an indirect effect in which it elicits a cellular antioxidant response by inducing ARE-controlled gene expression.

The molecular mechanisms underlying GSGa's cytoprotective effect on both NHDF and cMSC were here investigated using western blot analysis.

In both cMSC and NHDF, the treatment with GSGa also led to an increased expression of NQO1, and these results are also in agreement with previous findings [45]. NQO1 is one of the target proteins of the transcription factor Nrf2, involved in the antioxidant response of mammalian cells. NQO1's primary activity is the 2-electron reduction of endogenous and exogenous quinones to their corresponding hydroquinones through the use of either NADH or NADPH as the hydride donors, thus preventing the formation of radical species [66]. NQO1's antioxidant effects also correlate with its role in preserving a reduced pool of endogenous antioxidant molecules and stabilizing the tumor suppressor protein p53 [67]. The activity of antioxidant enzymes is regulated in the cell by the Nrf2-antioxidant response element (ARE) pathway. Nrf2 is a transcription factor normally found in the cytoplasm bound to the Kelch-like ECH-associated protein 1 (Keap1), which acts as a substrate adaptor protein for the Cullin3 (Cul3)-containing E3-ligase complex. The interaction between the aforementioned complex and Keap1 leads to Nrf2 ubiquitination and, eventually, to its degradation [68]. During oxidative stress, Keap1 undergoes structural modifications that result in the exposure of lysine residues, which become targets for ubiquitination and subsequent degradation [69]. Similarly, H_2S is able to induce the dissociation between Nrf2 and Keap1 through the sulfhydrylation of the Cys151 residue on Keap1 [70]. Nrf2 is therefore free to translocate to the nucleus where it binds to ARE (Figure 10).




Figure 10. Schematic representation of Nrf-2 activation of ARE by H_2S . Keap 1, Kelch-like ECH-associated protein 1; Nrf2, nuclear erythroid factor 2-related factor 2; ARE, antioxidant response elements; NQO1, NAD(P)H quinone oxidoreductase 1; HO1, heme oxygenase 1; CBS, cystathionine β -synthase; CSE, cystathionine γ -lyase.

The activation of extracellular signal-regulated kinases ERK1/2 and Akt, also known as protein kinase B, was observed after GSGa treatment in both cMSC and NHDF (see also Figure S6a in the Supplementary Materials). ERK1/2, belonging to the Ras-Raf-MEK-ERK signal transduction cascade, are involved in the regulation of several cellular processes such as cell adhesion, cell cycle progression, cell migration, cell survival, differentiation, metabolism, proliferation and transcription [71]. The activation of ERK1/2 follows the phosphorylation of the residues Tyr 204/187 and Thr 202/185 by MEK [71]. ERK1/2 targets include hundreds of cytoplasmic or nuclear substrates involved in different cellular processes. ERK1/2 could be responsible for the pro-survival and anti-apoptotic effect of GSGa, considering that an increased activation of ERK1/2 (p-ERK1/2) was observed in treated cMSC compared to control. Akt activation has also been associated with numerous crucial cell functions, such as proliferation, differentiation, cell migration, survival and angiogenesis [72].

This marked activation of Akt was also in agreement with the effect induced by H₂S-releasing agents on normal cells and BMSCs [45,73,74]. Therefore, our results are in agreement with recent findings that link H₂S pro-survival effects to the activation of the PI3K/Akt pathway [72,75,76].

GSGa treatment of cMSCs also led to increased expression of the proteins α -smooth muscle actin (α -SMA) and Cx43. Their increased expression can be linked to a commitment of the cells towards a cardiac phenotype. Cx43, in fact, is the most abundant isoform of gap-junction channels in cardiac tissue and its increased expression is also in agreement with our previous data obtained using H₂S-releasing nanoemulsions [40]. Generally, Cx43 expression is low in MSC [77], while high Cx43 expression in MSC can improve their survival and cardiomyogenesis after transplantation [78,79].

Thus, the therapeutic efficacy of cardiac progenitor/stem cell transplantation could be enhanced by the overexpression of Cx43 because it promotes neovascularization, reduces infarct size and preserves cardiac function preservation in the ischemic heart [80–82]. Cell therapy using MSC overexpressing Cx43 reduces infarct size, improving the heart functionality [74,80]. These results suggest a possible use of GSGa preconditioning of cMSC for improving their survival and eventually potentiate their ability to promote cardiac muscle tissue repair.

Thanks to the cytoprotective properties of H₂S-donors, the preconditioning of stem cells before their transplantation has recently gained attention. H₂S-donors are, without a doubt, promising exploitable tools to overcome the massive cell death that occurs after the implantation of stem cells in the site of injury for stem cell therapy. Currently, not many studies have investigated the use of H₂S-donors in tissue repair, and most of them are focused on short-term preconditioning of the stem cells prior to transplantation. The time-span of the pretreatment varies from as short as 30 min to 48–72 h [45,81,82]. A selected cell line named GcMSC was obtained after long-term preconditioning and was here characterized. GcMSCs were more resistant to the oxidative stress and further addition of GSGa to the medium of the GcMSC culture, and led to a survival higher than that obtained with only the addition of GSGa without preconditioning. This result suggests that the combination of these two approaches might be the best choice for potential in vivo applications.

This increased resistance to the oxidative stress was also in agreement with higher levels of expression of proteins associated with pro-survival/proliferation, such as pERK-1, p-Akt, Bcl2 and Trx1, in GcMSC compared to those in cMSC (Figure 6e). One of the most important features of a successful stem-cell based therapy is the ability of the implanted cells to migrate to the site of injury, proliferate and eventually differentiate in order to replace the damaged tissue. The cell migration ability was tested using both the percentage of scratch wound closure and the trans-well migration, and in both cases, the GcMSC migration was significantly higher than that of cMSC.

These results are in agreement with the recent studies that demonstrate that H₂S is able to promote migration and wound healing. The underlying mechanism involves increased levels of p-Akt, p-ERK1/2 and phosphorylated glycogen synthase kinase-3 β [81–83]. Overall these results demonstrate that prolonged cell GSGa pre-conditioning could represent a powerful tool for selecting adult stem-cell lines that maintain an increased proliferative and migration capability and resistance to oxidative stress, suggesting a potential successful approach for future in vivo/therapeutic applications. GcMSC

were able to differentiate into different cell types and the analyses performed did not show any relevant differences between the cell plasticity of GcMSC and cMSC.

The microarray data analysis showed that 52.5% of the genes, whose expression was altered upon the GSGa treatment, (+GSGa), were linked to the cardiovascular system/cardiovascular diseases, neurodegenerative diseases and diabetes. As previously stated, the study of the effects of H₂S on pathological conditions is focused mainly on the field of cardiovascular and neurodegenerative diseases. The first report of an H₂S cytoprotective effect goes back to 1996, when Abe and Kimura reported a beneficial role of NaHS in inducing long-term potentiation of the hippocampus at micromolar concentrations [84]. After that, interest gradually increased and other roles of this *gasotransmitter* in the central nervous system (CNS) and in neurodegenerative diseases were reported. In particular, H₂S concentration is relatively high in the brain, due to the tissue-specific expression of CBS. Indeed, H₂S has been reported to enhance N-methyl-D-aspartate (NMDA) receptor-mediated responses and to modulate Ca²⁺ and pH homeostasis in neurons, microglial cells and astrocytes [85]. Exogenous administration of H₂S has been therefore seen as a potential therapeutic tool for the cure of several CNS diseases including Alzheimer's disease, Parkinson's disease, ischemic stroke and traumatic brain injury [86]. H₂S also plays a central role in regulating cardiovascular system homeostasis. Changes in endogenous H₂S levels have been correlated to many diseases, including heart failure, myocardial ischaemia and atherosclerosis [87]. On this basis, our results are in agreement with the effects of other H₂S donors on cardiovascular and neurodegenerative diseases and suggest the possible value of investigating other potential target proteins whose expression can be regulated upon treatment with the natural H₂S-donor GSGa.

4. Materials and Methods

4.1. Preparation of Water-Soluble Extracts from *Allium sativum* L. and H₂S-Release Assay

The garlic water-soluble extracts (GaWS and GSGa) were prepared as previously described [16]. Briefly, 5 g of garlic cloves were crushed in 50 mM Tris-HCl buffer at pH 7.5 at room temperature for about 5–10 min with or without 10 mM reduced glutathione (GSH) and then the crushing procedure was continued in liquid N₂. After centrifugation, the water soluble fraction was stored at –20 °C for molecular characterization by RP-HPLC. RP-HPLC analysis was performed using mod. LC-10AVP (Shimadzu, Milan, Italy), equipped with a UV detector (Shimadzu, Milan, Italy) and a C₁₈ column (150 mm × 4.6 mm, 5 μm, CPS Analytica, Rome, Italy). The solvent B gradient (solvent B: 80% CH₃CN, 0.1% TFA; solvent A: 0.1% TFA) used was: 0–5 min, 0%; 5–55 min, 60%; 55–60 min, 60% and 65–85 min 90%. The elution was monitored at 220 nm. To obtain the dry weight of the extract (and therefore its concentration), 100 μL of GSGa extract were lyophilized.

4.2. H₂S Release Assay

H₂S production and release by GSGa, GYY4137 and Na₂S was assessed by methylene blue assay as previously described [16]. Briefly, each sample with 1 mM dithiothreitol (DTT) in 50 mM Tris HCl, pH 7.4 (150 μL final volume) was incubated at 37 °C on a shaker for 30 min. After the incubation, 20 μL of solution I (20 mM N', N'-dimethyl-p-phenylene-diamine-dihydrochloride in 7.2 M HCl) and 20 μL of solution II (30 mM FeCl₃ in 1.2 M HCl) were added to each solution. After an incubation time of 10 min at room temperature, coupled to gentle mixing of the solutions, absorbance was measured at 670 nm. Na₂S was used to elaborate a standard curve (Figure S1A in Supplementary Materials) and the H₂S- release from GYY4137 was also tested by MB assay and compared to that from GSGa (Figure S1B Supplementary Materials). All the results in this work were elaborated and plotted using GraphPad Prism version 5.0 software (GraphPad Software, San Diego, CA, USA).

4.3. Plasmid DNA Cleavage Inhibition Assay

These experiments were performed as previously described with minor modifications [40]. Briefly, reagents were added to a 0.5 mL microfuge tube in the following order: 0.5 µg of plasmid DNA, 20 mM Tris-HCl sterile pH 7.4 buffer, 10.8 mg/mL of GSGa, 100 µM of either H₂O₂ or CuCl₂ or CoCl₂ and 10 mM ascorbic acid, and sterilized ddH₂O to a final volume of 10 µL. After an incubation period of 15 min at 37 °C, the reactions were stopped by the addition of 2 µL of gel loading buffer (5% glycerol, 0.125% bromophenol blue, 25 mM EDTA) and freezing. Samples were kept on ice until electrophoresis in 0.8% agarose gel in TAE buffer.

4.4. Cell Viability Assay

Cell viability and proliferation were tested either by MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide [88] or WST-1(4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-benzene disulfonate (Cell Proliferation Reagent WST-1, Roche, Mannheim, Germany) [88] assay as indicated. After each treatment, the medium was replaced with fresh DMEM high glucose without phenol-red (Gibco, Life Technologies, Milan, Italy) containing tetrazolium salt WST-1 (5% *v/v*) or MTT (0.5 mg/mL). The cells were then incubated for 3 h at 37 °C, 5% CO₂. Absorbance of the medium was evaluated using a microplate reader at a wavelength of 450 nm for WST-1. For MTT assay, formazan crystals were solubilized with a solution of isopropanol and DMSO (1:1) and then the absorbance was measured at a wavelength of 570 nm.

4.5. Cell Migration

4.5.1. Scratch Wound Healing Assay

cMSC were seeded into 24-well plates (6.5×10^4 cells/cm²) and incubated overnight at 37 °C, 5% CO₂, so that the cells would reach confluency the next day. After 24 h, a scratch-wound was created with a 1 mL sterile pipette on the cell monolayer of each well. The medium was then removed and cells were washed twice with PBS; fresh medium was added to each well (800 µL/well). Area of the scratch-wound at time 0 and after 48 h was measured with ImageJ Software. Percentage of wound closure was measured as follows:

$$\text{Wound closure (\%)} = (\text{Wound surface area after 48 h} / \text{Wound surface area at time 0}) \times 100$$

4.5.2. Trans-Well Migration Assay

Cell migration was assessed using 8 µm-pore-size Falcon™ Cell Culture Inserts (Thermo Fisher Scientific, Milan, Italy). cMSC (0.1×10^6) were added on the upper chamber of the inserts in serum-free DMEM. Complete medium was added to the lower chamber of the inserts to attract the cells. After incubation for 6 h at 37 °C, 5% CO₂, cells were removed from the upper surface of the trans-well membrane with a water-wetted cotton swab. Cells that had migrated on the other side of the membrane were fixed and stained for 20 min with a solution containing 6% (*v/v*) glutaraldehyde and 0.5% (*w/v*) crystal violet in deionized water. The inserts were then washed repeatedly with water. Air-dried membranes were analyzed by optical microscopy.

4.6. Protection from Oxidative Stress

NHDF were seeded at a density of 3×10^3 cells/cm² and cultured for three days in the absence or in the presence of 680 µg/mL of GSGa. After that, the cells were reseeded at a density of 10^4 cells/cm² and after 6 h of incubation, the medium was replaced with fresh medium containing 100 µM of H₂O₂. After 12 h, cell survival was assessed by optical microscopy. Two different experiments were performed in order to analyze the anti-oxidant effect of GSGa treatment on cMSC. In the first one, cMSCs and GcMSCs were seeded at a density of 5×10^3 cells/cm² and after 24 h of growth the medium was replaced with fresh medium containing 100 µM of H₂O₂ with or without the addition of 680 µg/mL of

GSGa, GSH (100 μ M), Na₂S (100 μ M) or GYY4137 (300 μ M). After 24h, the medium was replaced with fresh DMEM medium (Gibco, Life Technologies, Milan, Italy) without phenol red and cell viability was assessed by WST-1 assay (Sigma-Aldrich, Milan, Italy). Cell cycle distribution analysis was performed by flow cytometry (FACS analysis) after 12 h of incubation. Briefly, cells (about 0.5×10^6) were harvested and stained with 50 μ g/mL propidium iodide (Sigma-Aldrich, Milan, Italy) for 30 min at 4 °C. After incubation, the samples were immediately analyzed using a FACSCalibur flow cytometer (Beckton and Dickinson, San Josè, CA, USA). The data obtained were then elaborated with the WinMDI free software. The second experiment was performed using cMSC and GcMSC that were seeded at a density of 10^4 cells/cm² and after 6 h of growth, the medium was replaced with fresh medium containing 100 μ M of H₂O₂. After 12 h of growth, cell survival was assessed by optical microscopy.

4.7. cMSC and NHDF Cultures and Immunofluorescence Analyses

Cell studies were conducted on cMCS and NHDF (Lonza, Basel, Switzerland) cell lines. cMSC were extracted by auricular biopsies made during the course of coronary artery bypass surgery from patients after signing a written consent form as previously described [38–40,89,90]. Cell cultures were grown in DMEM (Dulbecco's modified Eagle medium) (Gibco, Life Technologies, Milan, Italy), containing 10% *v/v* FBS (Fetal Bovine Serum) (Gibco, Life Technologies, Milan, Italy), 1% *w/v* penicillin-streptomycin (Sigma-Aldrich, Italy), and 1% *w/v* L-glutamine (Sigma-Aldrich, Italy). To perform the microscopy analyses, cMSCs, after the treatment, were washed in PBS, fixed in PBS with 4% *v/v* PFA at 4 °C for 15 min, permeabilized with 0.2% *v/v* Triton X-100 (Sigma-Aldrich, Italy) for 30 min and after washing, were incubated with specific antibodies for immunofluorescence microscopy. The antibodies used were anti- α -smooth muscle actin (α -sma) mouse, anti-connexin-43 (Cx43) mouse (Sigma-Aldrich, Italy), anti-human troponin T2 (TNNT2), followed by the appropriate Alexa Fluor[®] 488 fluorochrome-conjugated secondary antibody (Invitrogen, Life Technologies, Milan, Italy). Nuclei were stained with Hoechst 33342 (Sigma-Aldrich, Italy). The cells were analyzed by fluorescence microscopy using a Nikon Filter microscope and Lucia G version 4.61 software.

4.8. Protein Extraction and Western Blot Analysis

Proteins were extracted from cMSCs using 100 μ L of RIPA buffer containing a protease inhibitor cocktail (Sigma-Aldrich, Italy) and pervanadate (Sigma-Aldrich, Italy) as phosphatase inhibitor and after 90 min of incubation in ice were sonicated for 10 sec at 0 °C. Samples were centrifuged for 10 min at 8000 rpm at 4 °C. Protein content was determined by BCA protein assay (Sigma-Aldrich, Milan, Italy), and the SDS-PAGE of cell extracts (30 μ g of protein) were performed using 12 or 15% polyacrylamide gel. PVDF membranes (Sigma-Aldrich, Italy) were used for electro-blotting and were then blocked and probed with primary monoclonal antibodies (Ab-ERK1/2 rabbit, Ab-p-ERK1/2 rabbit, Ab-Trx rabbit, Ab-NQO1 rabbit, Ab-Akt and Ab-pAKT-(pSer473) rabbit, A, Ab- α -sma rabbit, b-Cx43 rabbit) (Sigma-Aldrich, Italy,) overnight at 4 °C. Immunoblots were next processed with secondary antibodies (Sigma-Aldrich, Italy) for 2 h at room temperature. Immunoblot with Ab-GAPDH rabbit or Ab- β -tubulin mouse (Sigma-Aldrich Italia, Milan Italy) were also probed for controlling the protein loading. The protein complex formed upon incubation with specific secondary antibodies (dilution 1:10000) (Sigma-Aldrich, Milan, Italy). Immunoblots were probed with a Super Signal West Pico kit (Thermo Scientific, Milan, Italy) to visualize signal, followed by exposure to Fluorchem Imaging system (Alpha Innotech Corporation-Analitica De Mori, Milan, Italy) or using a X-ray film (Kodak, Sigma-Aldrich, Italy).

4.9. Cell Differentiation

Control untreated cMSC and those pre-treated for one month with 140 μ g/mL of GSGa (GcMSCs) were seeded in 35 mm dishes at a density of 5000 cells/cm² until they reached a confluency of 80–90%. For adipogenic and osteogenic differentiation, the cells were stimulated for 3 days in the differentiation mediums, StemPro[®] Adipogenesis Differentiation Kit and StemPro[®] Chondrogenesis Differentiation

Kit (Gibco, Life Technologies, Milan, Italy), respectively. After 3 days, the medium was removed and the cells were washed twice with PBS and fixed with 4% *v/v* PF for 20 min at room temperature in the dark. Cells were then washed once with PBS, stained with Alcian Blue pH 2.5 to detect chondrogenic differentiation or Adipo Red for the adipogenic differentiation and analyzed by optical and fluorescent microscopy, respectively. For osteogenic differentiation, confluent cells were stimulated for 3 days with DMEM supplemented with 10% FBS, 1% *w/v* penicillin-streptomycin (Sigma-Aldrich, Italy), 1% *w/v* L-glutamine (GIBCO, Life Technologies, Milan, Italy), 1% *v/v* non-essential amino acids solution (Sigma-Aldrich, Italy), 50 µg/mL ascorbic acid, 10 mM β-glycerophosphate and 10 nM dexamethasone. After the stimulation period, the cells were stained with Alizarin Red dye and analyzed by optical microscopy. Cardiogenic differentiation was performed following the instructions provided with the Human Cardiomyocyte Immunocytochemistry Kit[®] (Life Technologies, Milan, Italy); after differentiation, cells were fixed as previously described and stained with a primary mouse anti-human troponin T2 (TNNT2) antibody and an Alexa Fluor[®] 488 donkey anti-mouse secondary antibody.

4.10. Microarray

RNA was extracted from cells, using a RNAeasy Kit (Qiagen, Manchester, UK). RNA was reverse transcribed, converted to cDNA, amplified, and labeled with a cyanine-3 dye using a Low Input Quick Amp labeling kit from Agilent. Labeled cRNAs were hybridized to human gene expression microarrays (Agilent, Cheshire, UK). The data were extracted using the Agilent Feature Extraction software (version 10.7.3.1) and analyzed using Agilent GeneSpring GX software (version 12.1, Agilent, Cheshire, UK). An unpaired Student's *t* test with Benjamini–Hochberg multiple testing correction was applied in order to analyze significant differences of expression, mRNAs with a *p* value of less than or equal to 0.05 and a fold change of greater than 1.5 were considered to be both statistically significant. Heat-maps were generated by Agilent GeneSpring GX software (version 12.1) with a hierarchical clustering algorithm based on normalized intensity value by using Euclidean similarity measurements (cut-off *p* value 0.05; cut-off fold change 1.5). Microarray analyses were performed using the DAVID 6.8 program [91,92] and InteractiVenn webtool (<http://www.interactivenn.net>).

4.11. Statistical Analysis

GraphPad Prism version 6.0 for Windows (GraphPad Software, San Diego, CA, USA) was used for the statistical analysis. Data obtained from three or five independent experiments were quantified and analyzed for each variable using a one-way ANOVA test or in some cases one-tailed Student's *t*-test. A *p* value of < 0.05 was considered to be statistically significant. Standard deviations or the standard error means were calculated and presented for each experiment.

5. Conclusions

The endogenous H₂S levels help regulating the equilibrium of several organs, including the respiratory, reproductive, neuronal, renal, cardiovascular, gastrointestinal and liver systems. The broad physiological role of this lipid-soluble gasotransmitter is due to its membrane permeability, although its unique chemical reactivity towards some macromolecules in different cell lines makes this gas a selective signalling molecule. Here a garlic water-soluble extract obtained with glutathione conjugation was used as a natural H₂S-releasing agent to analyse the effects of both acute and prolonged preconditioning on progenitor stem cells. Although the protective effect of H₂S by the oxidative stress was well investigated in the human cells using NaHS as H₂S donor [1,41], the effects of potential nutraceutical bio-products, such as GSGa, on MSC has not yet been assessed. Several studies suggest that the inherent reparative capability of the body could in theory be supported by incrementing the efficiency of the endogenous MSC via therapeutic exogenous MSC [93–95].

One of the most relevant problems in cell-based therapy is the optimization of the stem cell delivery system and of the capability of multipotent stem cells to proliferate, migrate and differentiate,

generally, in compromised sites where active oxidative and inflammatory processes are ongoing, with the aim of improving tissue repair and regeneration.

We demonstrated that the cell line selection by GSGa conditioning significantly improves the ability of the cMSC to proliferate, migrate and survive oxidative injury by activation of the expression of both HRE- and ARE-mediated transcription genes. The subsequent increase in antioxidant enzymes and molecules might protect against cellular senescence induced by oxidative stress. Moreover, we demonstrated that the prolonged GSGa treatment does not affect the cell plasticity of cMSC, although it improves the expression of proteins such as α -SMA and Cx43, which are important in muscle tissue commitment. The results presented here suggest the possibility of ameliorating MSC therapy by prolonged treatment with natural H₂S-releasing donors that could improve MSC homing to the site of injury, promoting their cell proliferation, migration and survival under oxidative stress conditions and ultimately favouring the capability of MSC to secrete paracrine factors with both immunoregulatory and structural functions for microenvironment regeneration.

Supplementary Materials: Supplementary Materials can be found at <http://www.mdpi.com/1422-0067/21/5/1638/s1>.

Author Contributions: Conceptualization and writing—original draft preparation, S.M.; investigation E.D.G., S.M., I.A. and S.B.; analysed the results, S.M., I.A., E.D.G., S.B.; writing manuscript, S.M., I.A. and E.D.G.; project administration, S.M.; funding acquisition, S.M. All authors reviewed the manuscript. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Acknowledgments: We thank Martina Colaicovo for technical support for the preliminary experiments, and P. Di Nardo for giving us the Lin⁻ Sca-1⁺ human cardiac MSC line.

Conflicts of Interest: The authors declare no conflict of interest.

Abbreviations

3-MTS	3-mercapto-piruvate sulfurtransferase;
α -SMA	α -smooth muscle actin;
AcH3	acetylated histone H3;
ACTN2	Actinin alpha 2;
Akt	Protein kinase B;
ARE	Antioxidant response element;
BAD-NE	BSA/ALA/DADS nanoemulsion;
BCA	bicinchoninic acid;
BMSCs	bone marrow mesenchymal stem cells;
CBS	cystathionine β -synthase;
CNS	central nervous system;
CSE	cystathionine γ -lyase;
Cx43	connexin-43;
cMSCs	Lin ⁻ Sca-1 ⁺ human cardiac progenitor cells;
DADS	diallyl-disulfide;
DMEM	Dulbecco's modified Eagle medium;
DATS	diallyl-trisulfide;
DU145	cells prostate cancer cell line;
ERK1/2	extracellular signal-regulated kinases 1/2;
FBS	Fetal Bovine Serum; H ₂ S, hydrogen sulfide;
HO1	heme oxygenase 1
Keep1	Kelch ECH associating protein 1;
MEF2C	myocyte enhancer factor 2C
MSCs	mesenchymal stem cells;
NHDF	normal human dermal fibroblasts;

NQO1	NAD(P)H quinoneoxidoreductase 1;
NMDA	N-methyl-D-aspartate;
Nrf2	nuclear factor erythroid 2-related factor 2;
NSAIDs	non-steroidal anti-inflammatory drugs;
OSCs	Organo-sulfur compounds;
p21	cyclin-dependent kinase inhibitor 1;
SGCD	sarcoglycan delta;
Trx1	thioredoxin 1;
TYRO3	tyrosine-protein kinase receptor;
SRFBP1	serum response factor binding protein 1;
TFA	trifluoroacetic acid;
TNNT2	human Troponin T2;
TST	thiosulfate: cyanide sulfurtransferase enzyme.

References

- Kimura, Y.; Dargusch, R.; Schubert, D.; Kimura, H. Hydrogen sulfide protects HT22 neuronal cells from oxidative stress. *Antioxid. Redox. Signal.* **2006**, *8*, 661–670. [[CrossRef](#)] [[PubMed](#)]
- Martelli, A.; Testai, L.; Breschi, M.C.; Blandizzi, C.; Viridis, A.; Taddei, S.; Calderone, V. Hydrogen sulphide: Novel opportunity for drug discovery. *Med. Res. Rev.* **2012**, *32*, 1093–1130. [[CrossRef](#)]
- Paul, B.D.; Snyder, S.H. H₂S: A Novel Gasotransmitter that Signals by Sulfhydration. *Trends Biochem. Sci.* **2015**, *40*, 687–700. [[CrossRef](#)] [[PubMed](#)]
- Eto, K.; Asada, T.; Arima, K.; Makifuchi, T.; Kimura, H. Brain hydrogen sulfide is severely decreased in Alzheimer's disease. *Biochem. Biophys. Res. Commun.* **2002**, *293*, 1485–1488. [[CrossRef](#)]
- Shibuya, N.; Mikami, Y.; Kimura, Y.; Nagahara, N.; Kimura, H. Vascular endothelium expresses 3-mercaptopyruvate sulfurtransferase and produces hydrogen sulfide. *J. Biochem.* **2009**, *146*, 623–626. [[CrossRef](#)] [[PubMed](#)]
- Kimura, H.; Shibuya, N.; Kimura, Y. Hydrogen sulfide is a signaling molecule and a cytoprotectant. *Antioxid. Redox Signal.* **2012**, *17*, 45–57. [[CrossRef](#)]
- Tang, G.; Wu, L.; Liang, W.; Wang, R. Direct stimulation of K(ATP) channels by exogenous and endogenous hydrogen sulfide in vascular smooth muscle cells. *Mol. Pharmacol.* **2005**, *68*, 1757–1764. [[CrossRef](#)]
- Bucci, M.; Papapetropoulos, A.; Vellecco, V.; Zhou, Z.; Pyriochou, A.; Roussos, C.; Roviezzo, F.; Brancaleone, V.; Cirino, G. Hydrogen sulfide is an endogenous inhibitor of phosphodiesterase activity. *Arterioscler. Thromb. Vasc. Biol.* **2010**, *30*, 1998–2004. [[CrossRef](#)]
- Sen, U.; Mishra, P.K.; Tyagi, N.; Tyagi, S.C. Homocysteine to hydrogen sulfide or hypertension. *Cell Biochem. Biophys.* **2010**, *57*, 49–58. [[CrossRef](#)]
- Dawe, G.S.; Han, S.P.; Bian, J.S.; Moore, P.K. Hydrogen sulphide in the hypothalamus causes an ATP-sensitive K⁺ channel-dependent decrease in blood pressure in freely moving rats. *Neuroscience* **2008**, *152*, 169–177. [[CrossRef](#)]
- Wallace, J.L.; Wang, R. Hydrogen sulfide-based therapeutics: Exploiting a unique but ubiquitous gasotransmitter. *Nat. Rev. Drug Discov.* **2010**, *14*, 329–345. [[CrossRef](#)] [[PubMed](#)]
- Mard, S.A.; Neisi, N.; Solgi, G.; Hassanpour, M.; Darbor, M.; Maleki, M. Gastroprotective effect of NaHS against mucosal lesions induced by ischemia-reperfusion injury in rat. *Dig. Dis. Sci.* **2012**, *57*, 1496–1503. [[CrossRef](#)] [[PubMed](#)]
- Benavides, G.A.; Squadrito, G.L.; Mills, R.W.; Patel, H.D.; Isbell, T.S.; Patel, R.P.; Darley-Usmar, V.M.; Doeller, J.E.; Kraus, D.W. Hydrogen sulfide mediates the vasoactivity of garlic. *Proc. Natl. Acad. Sci. USA* **2007**, *104*, 17977–17982. [[CrossRef](#)] [[PubMed](#)]
- Yang, G.; Sun, X.; Wang, R. Hydrogen sulfide-induced apoptosis of human aorta smooth muscle cells via the activation of mitogen-activated protein kinases and caspase-3. *Faseb. J.* **2004**, *18*, 1782–1784. [[CrossRef](#)] [[PubMed](#)]
- Cao, Q.; Zhang, L.; Yang, G.; Xu, C.; Wang, R. Butyrate-stimulated H₂S production in colon cancer cells. *Antioxid Redox Signal.* **2010**, *12*, 1101–1109. [[CrossRef](#)] [[PubMed](#)]

16. Bhuiyan, A.I.; Papajani, V.T.; Paci, M.; Melino, S. Glutathione-garlic sulfur conjugates: Slow hydrogen sulfide releasing agents for therapeutic applications. *Molecules* **2015**, *20*, 1731–1750. [[CrossRef](#)]
17. Bolton, S.G.; Cerda, M.M.; Gilbert, A.K.; Pluth, M.D. Effects of sulfane sulfur content in benzyl polysulfides on thiol-triggered H₂S release and cell proliferation. *Free Radic. Biol. Med.* **2019**, *131*, 393–398. [[CrossRef](#)]
18. Rose, P.; Moore, P.K.; Ming, S.H.; Nam, O.C.; Armstrong, J.S.; Whiteman, M. Hydrogen sulfide protects colon cancer cells from chemopreventative agent beta-phenylethyl isothiocyanate induced apoptosis. *World J. Gastroenterol.* **2005**, *11*, 3990–3997. [[CrossRef](#)]
19. Cai, W.J.; Wang, M.J.; Ju, L.H.; Wang, C.; Zhu, Y.C. Hydrogen sulfide induces human colon cancer cell proliferation: Role of Akt, ERK and p21. *Cell. Biol. Int.* **2007**, *34*, 565–572. [[CrossRef](#)]
20. Chuah, S.C.; Moore, P.K.; Zhu, Y.Z. S-allylcysteine mediates cardioprotection in an acute myocardial infarction rat model via a hydrogen sulfide-mediated pathway. *Am. J. Physiol. Heart Circ. Physiol.* **2007**, *293*, H2693–H2701. [[CrossRef](#)]
21. Deplancke, B.; Gaskins, H.R. Hydrogen sulfide induces serum-independent cell cycle entry in nontransformed rat intestinal epithelial cells. *Faseb. J.* **2003**, *17*, 1310–1312. [[CrossRef](#)] [[PubMed](#)]
22. Hu, L.F.; Lu, M.; Wu, Z.Y.; Wong, P.T.; Bian, J.S. Hydrogen sulfide inhibits rotenone-induced apoptosis via preservation of mitochondrial function. *Mol. Pharmacol.* **2009**, *75*, 27–34. [[CrossRef](#)] [[PubMed](#)]
23. Wang, H.C.; Pao, J.; Lin, S.Y.; Sheen, L.Y. Molecular mechanisms of garlic-derived allyl sulfides in the inhibition of skin cancer progression. *Ann. N. Y. Acad. Sci.* **2012**, *1271*, 44–52. [[CrossRef](#)] [[PubMed](#)]
24. Li, M.; Min, J.M.; Cui, J.R.; Zhang, L.H.; Wang, K.; Valette, A.; Davrinche, C.; Wright, M.; Leung-Tack, J. Z-ajoene induces apoptosis of HL-60 cells: Involvement of Bcl-2 cleavage. *Nutr. Cancer* **2002**, *42*, 241–247. [[CrossRef](#)] [[PubMed](#)]
25. Yin, X.; Zhang, R.; Feng, C.; Zhang, J.; Liu, D.; Xu, K.; Wang, X.; Zhang, S.; Li, Z.; Liu, X.; et al. Diallyl disulfide induces G2/M arrest and promotes apoptosis through the p53/p21 and MEK-ERK pathways in human esophageal squamous cell carcinoma. *Oncol. Rep.* **2014**, *32*, 1748–1756. [[CrossRef](#)] [[PubMed](#)]
26. Xiao, D.; Herman-Antosiewicz, A.; Antosiewicz, J.; Xiao, H.; Brisson, M.; Lazo, J.S.; Singh, S.V. Diallyl trisulfide-induced G(2)-M phase cell cycle arrest in human prostate cancer cells is caused by reactive oxygen species-dependent destruction and hyperphosphorylation of Cdc 25 C. *Oncogene* **2005**, *24*, 6256–6268. [[CrossRef](#)] [[PubMed](#)]
27. Xiao, D.; Zeng, Y.; Hahm, E.R.; Kim, Y.A.; Ramalingam, S.; Singh, S.V. Diallyl trisulfide selectively causes Bax- and Bak-mediated apoptosis in human lung cancer cells. *Environ. Mol. Mutagen.* **2009**, *50*, 201–212. [[CrossRef](#)]
28. Murai, M.; Inoue, T.; Suzuki-Karasaki, M.; Ochiai, T.; Ra, C.; Nishida, S.; Suzuki-Karasaki, Y. Diallyl trisulfide sensitizes human melanoma cells to TRAIL-induced cell death by promoting endoplasmic reticulum-mediated apoptosis. *Int. J. Oncol.* **2012**, *41*, 2029–2037. [[CrossRef](#)]
29. Chandra-Kuntal, K.; Lee, J.; Singh, S.V. Critical role for reactive oxygen species in apoptosis induction and cell migration inhibition by diallyl trisulfide, a cancer chemopreventive component of garlic. *Breast Cancer Res. Treat.* **2013**, *138*, 69–79. [[CrossRef](#)]
30. Dirsch, V.M.; Gerbes, A.L.; Vollmar, A.M. Ajoene, a compound of garlic, induces apoptosis in human promyeloleukemic cells, accompanied by generation of reactive oxygen species and activation of nuclear factor kappaB. *Mol. Pharmacol.* **1998**, *53*, 402–407. [[CrossRef](#)]
31. Osipov, R.M.; Robich, M.P.; Feng, J.; Chan, V.; Clements, R.T.; Deyo, R.J.; Szabo, C.; Sellke, F.W. Effect of hydrogen sulfide on myocardial protection in the setting of cardioplegia and cardiopulmonary bypass. *Interact. Cardiovasc. Thorac. Surg.* **2010**, *10*, 506–512. [[CrossRef](#)] [[PubMed](#)]
32. Elrod, J.W.; Calvert, J.W.; Morrison, J.; Doeller, J.E.; Kraus, D.W.; Tao, L.; Jiao, X.; Scalia, R.; Kiss, L.; Szabo, C.; et al. Hydrogen sulfide attenuates myocardial ischemia-reperfusion injury by preservation of mitochondrial function. *Proc. Natl. Acad. Sci. USA* **2007**, *104*, 15560–15565. [[CrossRef](#)] [[PubMed](#)]
33. Kloesch, B.; Liszt, M.; Krehan, D.; Broell, J.; Kiener, H.; Steiner, G. High concentrations of hydrogen sulphide elevate the expression of a series of pro-inflammatory genes in fibroblast-like synoviocytes derived from rheumatoid and osteoarthritis patients. *Immunol. Lett.* **2012**, *141*, 197–203. [[CrossRef](#)] [[PubMed](#)]
34. Oh, G.S.; Pae, H.O.; Lee, B.S.; Kim, B.N.; Kim, J.M.; Kim, H.R.; Jeon, S.B.; Jeon, W.K.; Chae, H.J.; Chung, H.T. Hydrogen sulfide inhibits nitric oxide production and nuclear factor-kappaB via heme oxygenase-1 expression in RAW264.7 macrophages stimulated with lipopolysaccharide. *Free Radic. Biol. Med.* **2006**, *41*, 106–119. [[CrossRef](#)]

35. Pan, L.L.; Liu, X.H.; Gong, Q.H.; Wu, D.; Zhu, Y.Z. Hydrogen sulfide attenuated tumor necrosis factor-alpha-induced inflammatory signaling and dysfunction in vascular endothelial cells. *PLoS ONE* **2011**, *6*, e19766. [[CrossRef](#)]
36. Tang, G.; Wu, L.; Wang, R. Interaction of hydrogen sulfide with ion channels. *Clin. Exp. Pharmacol. Physiol.* **2010**, *37*, 753–763. [[CrossRef](#)]
37. Predmore, B.L.; Lefer, D.J.; Gojon, G. Hydrogen sulfide in biochemistry and medicine. *Antioxid. Redox Signal.* **2012**, *17*, 119–140. [[CrossRef](#)]
38. Cacciotti, I.; Ciocci, M.; Di Giovanni, E.; Nanni, F.; Melino, S. Hydrogen Sulfide-Releasing Fibrous Membranes: Potential Patches for Stimulating Human Stem Cells Proliferation and Viability under Oxidative Stress. *Int. J. Mol. Sci.* **2018**, *19*, 2368. [[CrossRef](#)]
39. Mauretti, A.; Neri, A.; Kossover, O.; Seliktar, D.; Di Nardo, P.; Melino, S. Design of a Novel Composite H₂S-Releasing Hydrogel for Cardiac Tissue Repair. *Macromol. Biosci.* **2016**, *16*, 847–858. [[CrossRef](#)]
40. Ciocci, M.; Iorio, E.; Carotenuto, F.; Khashoggi, H.A.; Nanni, F.; Melino, S. H₂S-releasing nanoemulsions: A new formulation to inhibit tumor cells proliferation and improve tissue repair. *Oncotarget* **2016**, *7*, 84338–84358. [[CrossRef](#)]
41. Kimura, Y.; Kimura, H. Hydrogen sulfide protects neurons from oxidative stress. *Faseb. J.* **2004**, *18*, 1165–1167. [[CrossRef](#)] [[PubMed](#)]
42. Kimura, H. Physiological role of hydrogen sulfide and polysulfide in the central nervous system. *Neurochem. Int.* **2013**, *63*, 492–497. [[CrossRef](#)] [[PubMed](#)]
43. Hu, L.F.; Wong, P.T.; Moore, P.K.; Bian, J.S. Hydrogen sulfide attenuates lipopolysaccharide-induced inflammation by inhibition of p38 mitogen-activated protein kinase in microglia. *J. Neurochem.* **2007**, *100*, 1121–1128. [[CrossRef](#)] [[PubMed](#)]
44. Wang, D.G.; Zhang, F.X.; Chen, M.L.; Zhu, H.J.; Yang, B.; Cao, K.J. Cx43 in mesenchymal stem cells promotes angiogenesis of the infarcted heart independent of gap junctions. *Mol. Med. Rep.* **2014**, *9*, 1095–1102. [[CrossRef](#)]
45. Zhang, Q.; Liu, S.; Li, T.; Yuan, L.; Liu, H.; Wang, X.; Wang, F.; Wang, S.; Hao, A.; Liu, D.; et al. Preconditioning of bone marrow mesenchymal stem cells with hydrogen sulfide improves their therapeutic potential. *Oncotarget* **2016**, *7*, 58089–58104. [[CrossRef](#)]
46. Whiteman, M.; Armstrong, J.S.; Chu, S.H.; Jia-Ling, S.; Wong, B.S.; Cheung, N.S.; Halliwell, B.; Moore, P.K. The novel neuromodulator hydrogen sulfide: An endogenous peroxynitrite ‘scavenger’? *J. Neurochem.* **2004**, *90*, 765–768. [[CrossRef](#)]
47. Koike, S.; Ogasawara, Y.; Shibuya, N.; Kimura, H.; Ishii, K. Polysulfide exerts a protective effect against cytotoxicity caused by t-buthylhydroperoxide through Nrf2 signaling in neuroblastoma cells. *FEBS Lett.* **2013**, *587*, 3548–3555. [[CrossRef](#)]
48. Hurtado, B.; Munoz, X.; Recarte-Pelz, P.; Garcia, N.; Luque, A.; Krupinski, J.; Sala, N.; Garcia de Frutos, P. Expression of the vitamin K-dependent proteins GAS6 and protein S and the TAM receptor tyrosine kinases in human atherosclerotic carotid plaques. *Thromb. Haemost.* **2011**, *105*, 873–882. [[CrossRef](#)]
49. Chiu, C.; Bagnall, R.D.; Ingles, J.; Yeates, L.; Kennerson, M.; Donald, J.A.; Jormakka, M.; Lind, J.M.; Semsarian, C. Mutations in alpha-actinin-2 cause hypertrophic cardiomyopathy: A genome-wide analysis. *J. Am. Coll. Cardiol.* **2010**, *55*, 1127–1135. [[CrossRef](#)]
50. Tsubata, S.; Bowles, K.R.; Vatta, M.; Zintz, C.; Titus, J.; Muhonen, L.; Bowles, N.E.; Towbin, J.A. Mutations in the human delta-sarcoglycan gene in familial and sporadic dilated cardiomyopathy. *J. Clin. Invest.* **2000**, *106*, 655–662. [[CrossRef](#)]
51. Gary-Bobo, G.; Parlakian, A.; Escoubet, B.; Franco, C.A.; Clement, S.; Bruneval, P.; Tuil, D.; Daegelen, D.; Paulin, D.; Li, Z.; et al. Mosaic inactivation of the serum response factor gene in the myocardium induces focal lesions and heart failure. *Eur. J. Heart Fail.* **2008**, *10*, 635–645. [[CrossRef](#)] [[PubMed](#)]
52. Liu, D.; Wang, Z.; Zhan, J.; Zhang, Q.; Wang, J.; Xian, X.; Luan, Q.; Hao, A. Hydrogen sulfide promotes proliferation and neuronal differentiation of neural stem cells and protects hypoxia-induced decrease in hippocampal neurogenesis. *Pharmacol. Biochem. Behav.* **2014**, *116*, 55–63. [[CrossRef](#)] [[PubMed](#)]
53. Whiteman, M.; Li, L.; Rose, P.; Tan, C.H.; Parkinson, D.B.; Moore, P.K. The effect of hydrogen sulfide donors on lipopolysaccharide-induced formation of inflammatory mediators in macrophages. *Antioxid Redox Signal.* **2010**, *12*, 1147–1154. [[CrossRef](#)] [[PubMed](#)]

54. Chiku, T.; Padovani, D.; Zhu, W.; Singh, S.; Vitvitsky, V.; Banerjee, R. H₂S biogenesis by human cystathionine gamma-lyase leads to the novel sulfur metabolites lanthionine and homolanthionine and is responsive to the grade of hyperhomocysteinemia. *J. Biol. Chem.* **2009**, *284*, 11601–11612. [[CrossRef](#)]
55. Singh, S.; Padovani, D.; Leslie, R.A.; Chiku, T.; Banerjee, R. Relative contributions of cystathionine beta-synthase and gamma-cystathionase to H₂S biogenesis via alternative trans-sulfuration reactions. *J. Biol. Chem.* **2009**, *284*, 22457–22466. [[CrossRef](#)]
56. Sun, Q.; Collins, R.; Huang, S.; Holmberg-Schiavone, L.; Anand, G.S.; Tan, C.H.; van-den-Berg, S.; Deng, L.W.; Moore, P.K.; Karlberg, T.; et al. Structural basis for the inhibition mechanism of human cystathionine gamma-lyase, an enzyme responsible for the production of H(2)S. *J. Biol. Chem.* **2009**, *284*, 3076–3085. [[CrossRef](#)]
57. Wang, G.L.; Jiang, B.H.; Rue, E.A.; Semenza, G.L. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O₂ tension. *Proc. Natl. Acad. Sci. USA* **1995**, *92*, 5510–5514. [[CrossRef](#)]
58. Semenza, G.L. Hydroxylation of HIF-1: Oxygen sensing at the molecular level. *Physiology (Bethesda)* **2004**, *19*, 176–182. [[CrossRef](#)]
59. Dengler, V.L.; Galbraith, M.; Espinosa, J.M. Transcriptional regulation by hypoxia inducible factors. *Crit. Rev. Biochem. Mol. Biol.* **2013**, *49*, 1–15. [[CrossRef](#)]
60. Yang, C.; Yang, Z.; Zhang, M.; Dong, Q.; Wang, X.; Lan, A.; Zeng, F.; Chen, P.; Wang, C.; Feng, J. Hydrogen sulfide protects against chemical hypoxia-induced cytotoxicity and inflammation in HaCaT cells through inhibition of ROS/NF-kappaB/COX-2 pathway. *PLoS ONE* **2011**, *6*, e21971.
61. Mitsuhashi, H.; Yamashita, S.; Ikeuchi, H.; Kuroiwa, T.; Kaneko, Y.; Hiromura, K.; Ueki, K.; Nojima, Y. Oxidative stress-dependent conversion of hydrogen sulfide to sulfite by activated neutrophils. *Shock* **2005**, *24*, 529–534. [[CrossRef](#)] [[PubMed](#)]
62. Geng, B.; Chang, L.; Pan, C.; Qi, Y.; Zhao, J.; Pang, Y.; Du, J.; Tang, C. Endogenous hydrogen sulfide regulation of myocardial injury induced by isoproterenol. *Biochem. Biophys. Res. Commun.* **2004**, *318*, 756–763. [[CrossRef](#)] [[PubMed](#)]
63. Hildebrandt, T.M.; Grieshaber, M.K. Three enzymatic activities catalyze the oxidation of sulfide to thiosulfate in mammalian and invertebrate mitochondria. *FEBS J.* **2008**, *275*, 3352–3361. [[CrossRef](#)] [[PubMed](#)]
64. Tiranti, V.; Viscomi, C.; Hildebrandt, T.; Di Meo, I.; Mineri, R.; Tiverson, C.; Levitt, M.D.; Prella, A.; Fagioli, G.; Rimoldi, M.; et al. Loss of ETHE1, a mitochondrial dioxxygenase, causes fatal sulfide toxicity in ethylmalonic encephalopathy. *Nat. Med.* **2009**, *15*, 200–205. [[CrossRef](#)] [[PubMed](#)]
65. Viscomi, C.; Burlina, A.B.; Dweikat, I.; Savoiano, M.; Lamperti, C.; Hildebrandt, T.; Tiranti, V.; Zeviani, M. Combined treatment with oral metronidazole and N-acetylcysteine is effective in ethylmalonic encephalopathy. *Nat. Med.* **2010**, *16*, 869–871. [[CrossRef](#)] [[PubMed](#)]
66. Siegel, D.; Dehn, D.D.; Bokatzian, S.S.; Quinn, K.; Backos, D.S.; Di Francesco, A.; Bernier, M.; Reisdorph, N.; de Cabo, R.; Ross, D. Redox modulation of NQO1. *PLoS ONE* **2018**, *13*, e0190717. [[CrossRef](#)]
67. Asher, G.; Lotem, J.; Kama, R.; Sachs, L.; Shaul, Y. NQO1 stabilizes p53 through a distinct pathway. *Proc. Natl. Acad. Sci. USA* **2002**, *99*, 3099–3104. [[CrossRef](#)]
68. Villeneuve, N.F.; Lau, A.; Zhang, D.D. Regulation of the Nrf2-Keap1 antioxidant response by the ubiquitin proteasome system: An insight into cullin-ring ubiquitin ligases. *Antioxid. Redox Signal.* **2010**, *13*, 1699–1712. [[CrossRef](#)]
69. Zhang, D.D.; Lo, S.C.; Sun, Z.; Habib, G.M.; Lieberman, M.W.; Hannink, M. Ubiquitination of Keap1, a BTB-Kelch substrate adaptor protein for Cul3, targets Keap1 for degradation by a proteasome-independent pathway. *J. Biol. Chem.* **2005**, *280*, 30091–30099. [[CrossRef](#)]
70. Xie, L.; Gu, Y.; Wen, M.; Zhao, S.; Wang, W.; Ma, Y.; Meng, G.; Han, Y.; Wang, Y.; Liu, G.; et al. Hydrogen Sulfide Induces Keap1 S-sulfhydration and Suppresses Diabetes-Accelerated Atherosclerosis via Nrf2 Activation. *Diabetes* **2016**, *65*, 3171–3184. [[CrossRef](#)]
71. Roskoski, R., Jr. ERK1/2 MAP kinases: Structure, function, and regulation. *Pharmacol Res.* **2012**, *66*, 105–143. [[CrossRef](#)] [[PubMed](#)]
72. Rauch, J.; Volinsky, N.; Romano, D.; Kolch, W. The secret life of kinases: Functions beyond catalysis. *Cell Commun. Signal.* **2011**, *9*, 23. [[CrossRef](#)] [[PubMed](#)]
73. Papapetropoulos, A.; Pyriochou, A.; Altaany, Z.; Yang, G.D.; Marazioti, A.; Zhou, Z.M.; Jeschke, M.G.; Branski, L.K.; Herndon, D.N.; Wang, R.; et al. Hydrogen sulfide is an endogenous stimulator of angiogenesis. *Proc. Natl. Acad. Sci. USA* **2009**, *106*, 21972–21977. [[CrossRef](#)] [[PubMed](#)]

74. Altaany, Z.; Yang, G.; Wang, R. Crosstalk between hydrogen sulfide and nitric oxide in endothelial cells. *J. Cell Mol. Med.* **2013**, *17*, 879–888. [[CrossRef](#)]
75. Ersahin, T.; Tuncbag, N.; Cetin-Atalay, R. The PI3K/AKT/mTOR interactive pathway. *Mol. Biosyst.* **2015**, *11*, 1946–1954. [[CrossRef](#)]
76. Spassov, S.G.; Donus, R.; Ihle, P.M.; Engelstaedter, H.; Hoetzel, A.; Faller, S. Hydrogen Sulfide Prevents Formation of Reactive Oxygen Species through PI3K/Akt Signaling and Limits Ventilator-Induced Lung Injury. *Oxid. Med. Cell Longev.* **2017**, *2017*, 3715037. [[CrossRef](#)]
77. Pijnappels, D.A.; Schalij, M.J.; van Tuyn, J.; Ypey, D.L.; de Vries, A.A.; van der Wall, E.E.; van der Laarse, A.; Atsma, D.E. Progressive increase in conduction velocity across human mesenchymal stem cells is mediated by enhanced electrical coupling. *Cardiovasc. Res.* **2006**, *72*, 282–291. [[CrossRef](#)]
78. Lu, G.; Haider, H.K.; Jiang, S.; Ashraf, M. Sca-1+ stem cell survival and engraftment in the infarcted heart: Dual role for preconditioning-induced connexin-43. *Circulation* **2009**, *119*, 2587–2596. [[CrossRef](#)]
79. Wang, J.F.; Li, Y.; Song, J.N.; Pang, H.G. Role of hydrogen sulfide in secondary neuronal injury. *Neurochem. Int.* **2014**, *64*, 37–47. [[CrossRef](#)]
80. Hahn, J.Y.; Cho, H.J.; Kang, H.J.; Kim, T.S.; Kim, M.H.; Chung, J.H.; Bae, J.W.; Oh, B.H.; Park, Y.B.; Kim, H.S. Pre-treatment of mesenchymal stem cells with a combination of growth factors enhances gap junction formation, cytoprotective effect on cardiomyocytes, and therapeutic efficacy for myocardial infarction. *J. Am. Coll. Cardiol.* **2008**, *51*, 933–943. [[CrossRef](#)]
81. Ke, X.; Zou, J.; Hu, Q.; Wang, X.; Hu, C.; Yang, R.; Liang, J.; Shu, X.; Nie, R.; Peng, C. Hydrogen Sulfide-Preconditioning of Human Endothelial Progenitor Cells Transplantation Improves Re-Endothelialization in Nude Mice with Carotid Artery Injury. *Cell Physiol. Biochem.* **2017**, *43*, 308–319. [[CrossRef](#)] [[PubMed](#)]
82. Xie, X.; Sun, A.; Zhu, W.; Huang, Z.; Hu, X.; Jia, J.; Zou, Y.; Ge, J. Transplantation of mesenchymal stem cells preconditioned with hydrogen sulfide enhances repair of myocardial infarction in rats. *Tohoku J. Exp. Med.* **2012**, *226*, 29–36. [[CrossRef](#)] [[PubMed](#)]
83. Cheng, Z.; Garikipati, V.N.; Nickoloff, E.; Wang, C.; Polhemus, D.J.; Zhou, J.; Benedict, C.; Khan, M.; Verma, S.K.; Rabinowitz, J.E.; et al. Restoration of Hydrogen Sulfide Production in Diabetic Mice Improves Reparative Function of Bone Marrow Cells. *Circulation* **2016**, *134*, 1467–1483. [[CrossRef](#)] [[PubMed](#)]
84. Abe, K.; Kimura, H. The possible role of hydrogen sulfide as an endogenous neuromodulator. *J. Neurosci* **1996**, *16*, 1066–1071. [[CrossRef](#)] [[PubMed](#)]
85. Zhang, X.; Bian, J.S. Hydrogen sulfide: A neuromodulator and neuroprotectant in the central nervous system. *ACS Chem. Neurosci.* **2014**, *5*, 876–883. [[CrossRef](#)] [[PubMed](#)]
86. Smits, A.M.; van Vliet, P.; Metz, C.H.; Korfage, T.; Sluijter, J.P.; Doevendans, P.A.; Goumans, M.J. Human cardiomyocyte progenitor cells differentiate into functional mature cardiomyocytes: An in vitro model for studying human cardiac physiology and pathophysiology. *Nat. Protoc.* **2009**, *4*, 232–243. [[CrossRef](#)]
87. Pan, L.L.; Qin, M.; Liu, X.H.; Zhu, Y.Z. The Role of Hydrogen Sulfide on Cardiovascular Homeostasis: An Overview with Update on Immunomodulation. *Front. Pharmacol* **2017**, *8*, 686. [[CrossRef](#)]
88. Denizot, F.; Lang, R. Rapid colorimetric assay for cell growth and survival. Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability. *J. Immunol. Methods* **1986**, *89*, 271–277. [[CrossRef](#)]
89. Koyanagi, M.; Kawakabe, S.; Arimura, Y. A comparative study of colorimetric cell proliferation assays in immune cells. *Cytotechnology* **2016**, *68*, 1489–1498. [[CrossRef](#)]
90. Forte, G.; Pietronave, S.; Nardone, G.; Zamperone, A.; Magnani, E.; Pagliari, S.; Pagliari, F.; Giacinti, C.; Nicoletti, C.; Musaro, A.; et al. Human cardiac progenitor cell grafts as unrestricted source of supernumerary cardiac cells in healthy murine hearts. *Stem Cells* **2011**, *29*, 2051–2061. [[CrossRef](#)]
91. Huang, D.W.; Sherman, B.T.; Lempicki, R.A. Systematic and integrative analysis of large gene lists using DAVID Bioinformatics Resources. *Nature Protoc.* **2009**, *4*, 44–57. [[CrossRef](#)] [[PubMed](#)]
92. Huang, D.W.; Sherman, B.T.; Lempicki, R.A. Bioinformatics enrichment tools: Paths toward the comprehensive functional analysis of large gene lists. *Nucleic Acids Res.* **2009**, *37*, 1–13. [[CrossRef](#)] [[PubMed](#)]
93. Kim, H.; Bae, C.; Kook, Y.M.; Koh, W.G.; Lee, K.; Park, M.H. Mesenchymal stem cell 3D encapsulation technologies for biomimetic microenvironment in tissue regeneration. *Stem Cell Res. Ther.* **2019**, *10*, 51. [[CrossRef](#)] [[PubMed](#)]

94. Shi, Y.; Du, L.; Lin, L.; Wang, Y. Tumour-associated mesenchymal stem/stromal cells: Emerging therapeutic targets. *Nat. Rev. Drug Discov.* **2017**, *16*, 35–52. [[CrossRef](#)]
95. Shi, Y.; Wang, Y.; Li, Q.; Liu, K.; Hou, J.; Shao, C. Immunoregulatory mechanisms of mesenchymal stem and stromal cells in inflammatory diseases. *Nat. Rev. Nephrol.* **2018**, *14*, 493–507. [[CrossRef](#)]



© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<http://creativecommons.org/licenses/by/4.0/>).